País: Canadá
Língua: inglês
Origem: Health Canada
DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE)
PRO DOC LIMITEE
N06AX23
DESVENLAFAXINE
50MG
TABLET (EXTENDED-RELEASE)
DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE) 50MG
ORAL
15G/50G
Prescription
Active ingredient group (AIG) number: 0152509001; AHFS:
APPROVED
2022-04-29
_PRO-DESVENLAFAXINE PRODUCT MONOGRAPH _ PAGE 1 OF 50 PRODUCT MONOGRAPH PR PRO-DESVENLAFAXINE Desvenlafaxine Extended-Release Tablets 50 mg and 100 mg desvenlafaxine (as desvenlafaxine succinate) ANTIDEPRESSANT DATE OF REVISION: JAN 10, 2023 CONTROL NUMBER: 270605 PRO DOC LTÉE 2925 BOULEVARD INDUSTRIEL LAVAL, QUEBEC H7L 3W9 _PRO-DESVENLAFAXINE PRODUCT MONOGRAPH _ PAGE 2 OF 50 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 3 SUMMARY PRODUCT INFORMATION ................................................................................ 3 INDICATIONS AND CLINICAL USE ..................................................................................... 3 CONTRAINDICATIONS ........................................................................................................... 4 WARNINGS AND PRECAUTIONS ......................................................................................... 4 ADVERSE REACTIONS ......................................................................................................... 11 DRUG INTERACTIONS ......................................................................................................... 22 DOSAGE AND ADMINISTRATION ..................................................................................... 25 OVERDOSAGE ........................................................................................................................ 27 ACTION AND CLINICAL PHARMACOLOGY .................................................................... 29 STORAGE AND STABILITY ................................................................................................. 32 SPECIAL HANDLING INSTRUCTIONS ............................................................................... 32 DOSAGE FORMS, COMPOSITION AND PACKAGING ..................................................... 32 PART II: SCIENTIFIC INFORMATION ............................................................................... 33 PHARMACEUTICAL INFORM Leia o documento completo